Evidence map›Paper›PMID 27293826›Full record

ArticleJournal of thoracic disease2016

High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.

Likun Hou, Shengxiang Ren, Bo Su, Liping Zhang, Wei Wu, Wei Zhang, Zhengwei Dong, Yan Huang, Chunyan Wu, Gang Chen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Chr1Journal of thoracic disease · 2021
    Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Likun Hou1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Shengxiang Ren1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Bo Su1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Liping Zhang1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Wei Wu1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Wei Zhang1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhengwei Dong1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yan Huang1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Chunyan Wu1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Gang Chen1 Department of Pathology, 2 Department of Medical Oncology, 3 Central Lab, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China ; 4 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Shanghai Pulmonary Hospital · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNZhongshan Hospital · CNFudan University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer has heterogeneous features. It remains unclear whether ALK rearrangement was distributed heterogeneously in tumor from different anatomic sites. To address this issue, we investigate the concordance of ALK rearrangement between primary tumors and paired metastatic lymph nodes in pulmonary adenocarcinoma patients.

methodsFrom Sep 2013 to May 2014, resectable lung adenocarcinoma patients with EGFR wildtype and paired metastatic lymph nodes from Tongji University affiliated Shanghai pulmonary hospital were selected into this study. An auto-mated Ventana ALK with clone D5F3 antibody immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction (RT-PCR) were used to detected ALK rearrangement. Discordant cases between IHC and RT-PCR were further validated by fluorescence in situ hybridization (FISH).

resultsA total of 101 patients were enrolled into this study with a median age of 60 years old (range, 35-78 years). ALK rearrangement was found in 20 primary lesions, while in 18 paired metastatic lymph nodes. ALK rearrangement was more frequently happened in younger (P<0.001), Nonsmokers (P=0.012), high-stage disease (P=0.021) and predominantly solid growth pattern (P=0.024). The concordance rate between primary tumor and paired metastatic lymph nodes was 98%. Two patients with ALK rearrangement on primary tumor didn't show ALK gene fusion on paired metastatic lymph nodes. Sixty-eight cases had more than two stations of metastatic lymph nodes. ALK rearrangement in the different station of metastatic lymph nodes of the same patient was consistent.

conclusionsHigh concordant rate of ALK rearrangement between primary tumors and paired metastatic lymph nodes were found in this study. The authors concluded that specimens from metastatic lesions and primary tumors are equally suitable for detection ALK rearrangement.

Indexed as

ALK rearrangementfluorescence in situ hybridization (FISH)heterogeneityimmunohistochemistry (IHC)lung adenocarcinomareverse transcriptase-polymerase chain reaction (RT-PCR)

Identifiers

PMID27293826
PMCPMC4885982
OpenAlexW2341435787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.